Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2015
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).
Epistemonikos ID: ec162d9276b45b1da8287b2554752e21ead08c24
First added on: Nov 24, 2021